Latest Regeneron News & Updates

See the latest news and media coverage for Regeneron. We track all announcements, press releases, and industry mentions in real time, all in one place.

Regeneron

Biopharmaceutical company

regeneron.com

Headquarters: Tarrytown, United States
Company type: Public company
Number of employees: 15,000+
Industry: Pharmaceuticals

Last updated Today

Latest news about Regeneron

In short: Regeneron surpassed Q2 2026 expectations, received FDA approval for Pasatru, and advanced multiple therapies into regulatory review.

Company announcements

July 30 Regeneron

Regeneron reported strong Q2 2026 financial results with 17% revenue growth

Revenues increased to $4.3 billion, driven by Dupixent and EYLEA HD sales. GAAP EPS was $12.23, non-GAAP EPS $14.29.

July 29 Regeneron

Regeneron mourns the passing of director Art Ryan

He served on the board for over two decades and was a trusted advisor.

June 22 Regeneron

Regeneron announces FDA and EMA accept cemdisiran submissions for gMG

NDA under Priority Review with action date November 2026; EU decision expected H2 2027. Cemdisiran could be first siRNA for gMG with subcutaneous dosing four times a year.

May 28 Regeneron

Regeneron's Ebola antibody recommended by WHO for investigational use

The antibody, maftivimab, has shown broad activity against Bundibugyo virus in vitro and will be evaluated in clinical trials.

Media coverage

September 10 Yahoo Finance

Regeneron Pharmaceuticals More Likely to Retain Eylea HD Patent, RBC Says

Regeneron Pharmaceuticals' (REGN) patent on Eylea HD is more likely to be retained, with the Patent Trial and Appeal Board, or PTAB, due to issue...

September 3 Pharmaceutical Executive

Trump Administration Adds Nine Drugmakers to Most-Favored-Nation Program: Report | PharmExec

Johnson & Johnson, AbbVie, Regeneron, Alcon, Astellas Pharma, BeOne Medicines, BridgeBio, CSL, Kyowa Kirin, Sun Pharma, Teva Pharmaceuticals, and UCB.1...

August 25 TipRanks

Regeneron and Sanofi Advance IL-33 Strategy With Completed Rhinosinusitis Trial - TipRanks.com

Regeneron Pharmaceuticals ($REGN), Sanofi ($SNYNF) announced an update on their ongoing clinical study. The study titled “A Randomized, Double-blind, Placebo-contro...

August 20 Yahoo Finance

Regeneron Pharmaceuticals (REGN) Adjusts Course Amid Mixed Results in Melanoma Drug Trials

Sound Shore Management, an investment management firm, has released its investor letter for the second quarter of 2026. The letter can be downloaded here. The...

Never miss news about Regeneron

Track Regeneron and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Regeneron competitors & trending companies

Browse news for competitors to Regeneron and other trending companies.